Ratings for MetLife (NYSE:MET) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 7 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 0 | 0 | 0 |
| 3M Ago | 0 | 4 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $84.0, a high estimate of $87.00, and a low estimate of $80.00. Witnessing a positive shift, the current average has risen by 1.89% from the previous average price target of $82.44.
Exploring Analyst Ratings: An In-Depth Overview
A clear picture of MetLife's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Suneet Kamath | Jefferies | Lowers | Buy | $83.00 | $88.00 |
| Kevin Heal | Argus Research | Raises | Buy | $80.00 | $77.00 |
| Elyse Greenspan | Wells Fargo | Lowers | Overweight | $85.00 | $86.00 |
| Ryan Krueger | Keefe, Bruyette & Woods | Lowers | Outperform | $86.00 | $87.00 |
| John Barnidge | Piper Sandler | Lowers | Overweight | $82.00 | $85.00 |
| Nigel Dally | Morgan Stanley | Raises | Overweight | $82.00 | $80.00 |
| Elyse Greenspan | Wells Fargo | Raises | Overweight | $86.00 | $83.00 |
| Ryan Krueger | Keefe, Bruyette & Woods | Raises | Outperform | $87.00 | $82.00 |
| John Barnidge | Piper Sandler | Raises | Overweight | $85.00 | $74.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MetLife. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MetLife compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of MetLife's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MetLife's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on MetLife analyst ratings.
Get to Know MetLife Better
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial services products. The company is organized into five segments: us, Asia, Latin America, EMEA, and MetLife Holdings. The U.S. business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile with the Latin America segment contributing around 13% of earnings. The EMEA and the MetLife segments contribute around 4% and 11% of earnings, respectively.
A Deep Dive into MetLife's Financials
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: MetLife's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 2.89%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.03%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): MetLife's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.73%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): MetLife's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.12%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: MetLife's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.67, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.